Showing results 2 to 6 of 6
< previous
Title | Author(s) | Issue Date | |
---|---|---|---|
CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM) Proceeding/Conference:Journal of Clinical Oncology | 2010 | ||
Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance) Proceeding/Conference:Journal of Clinical Oncology | 2015 | ||
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and leukemia group B 30601): A brief report Journal:Journal of Thoracic Oncology | 2012 | ||
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303 Proceeding/Conference:Journal of Clinical Oncology | 2011 | ||
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance) Journal:Clinical Cancer Research | 2013 |